- Home
- SLS vs ADAM Comparison
SLS vs ADAM Comparison
Compare SLS & ADAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | ADAM |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | 221 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 826.7M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLS | ADAM |
|---|---|---|
| Price | $8.12 | $9.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $9.17 |
| AVG Volume (30 Days) | ★ 9.0M | 571.9K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 11.87% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $110.98 | $5.08 |
| P/E Ratio | ★ N/A | $41.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $6.45 |
| 52 Week High | $9.51 | $9.52 |
Technical Indicators
Market Signals| Indicator | SLS | ADAM |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 55.18 |
| Support Level | $7.07 | $7.72 |
| Resistance Level | $9.51 | $9.24 |
| Average True Range (ATR) | 0.66 | 0.22 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 44.27 | 49.32 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About ADAM Adamas Trust Inc.
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.